“A ureteral stent can be bothersome, but it’s quite variable. Some people don’t even feel the stent and some people have severe symptoms,” says Johnathan Harper, MD.
Lead study author Johnathan Harper, MD discusses the background and results of the study, “Risk Factors For Increased Stent-Associated Symptoms Following Ureteroscopy For Urinary Stones: Results From The Urinary Stone Disease Research Network (USDRN) Stents Study,” which he presented at the 2022 AUA Annual Meeting (abstract LBA02-08).
Harper is a professor of Urology and chief of Endourology and Minimally Invasive Surgery at the University of Washington
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.